4.1 Article

Health-related quality of life and cognitive failures in patients with lower-grade gliomas treated with radiotherapy

期刊

CANCER RADIOTHERAPIE
卷 27, 期 3, 页码 219-224

出版社

ELSEVIER
DOI: 10.1016/j.canrad.2022.10.004

关键词

Lower-grade glioma; Quality of life; Cognition; Radiotherapy

向作者/读者索取更多资源

This study evaluated the health-related quality of life (HRQOL) and cognitive failures in low-grade glioma (LGG) patients who had been previously treated with radiotherapy (RT). The results showed that these patients had significant impairments in HRQOL and cognitive functioning after treatment. Further efforts are needed to improve the quality of life and cognitive outcomes of LGG patients.
Purpose.- Patients with lower grade (grade 2 and 3) glioma (LGG) frequently experience prolonged clinical course after multimodal therapy (including surgery, radiotherapy (RT), and chemotherapy). There is therefore significant concern about the potential long-term impact of the disease and treatments onquality of life (QOL) and cognitive functioning. In this context, we evaluated health related QOL and cognitive failures in LGG patients previously treated in our RT department. Patients and methods. - Adult LGG patients previously treated with RT were prospectively included. Patients were evaluated based on standardized questionnaires [i.e., EORTC QLQ-C30, EORTC QLQ-BN20, and cognitive failures questionnaire (CFQ)]. Results. - Forty-eight patients were included. Median time elapsed since the end of RT was 59.5 months( range: 4-297). Based on EORTC QLQ-C30 and QLQ-BN20, the most prevalent HRQOL issues were impaired cognitive functioning (50% of the patients), impaired emotional functioning (47.9%), financial difficulties( 43.7%), fatigue (43.7%), future uncertainty (39.6%), and impaired physical functioning (35.4%). Based on the CFQ, 35.4% of the patients showed increased tendency to cognitive failures. Conclusion. - Patients with LGG frequently experience impairments in HRQOL and cognitive failures after treatment (including RT). Further efforts are therefore warranted to improve the QOL and cognitive outcome of these patients. (c) 2023 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. Allrights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据